Your browser doesn't support javascript.
Evaluation of the Effect of Underlying Diseases on Mortality of COVID-19 Patients: A Study of 19,985 Cases
Jundishapur Journal of Microbiology ; 15(11) (no pagination), 2022.
Article in English | EMBASE | ID: covidwho-2274237
ABSTRACT

Background:

The outbreak of a new coronavirus in China in 2019 (COVID-19) caused a global health crisis. Objective(s) This study was performed to investigate the effect of different underlying diseases on mortality in patients with COVID-19. Method(s) This retrospective cohort study was performed on COVID-19 patients admitted to the Shahid Rahimi and Sohada-ye Ashayer teaching hospitals in Khorramabad, Iran, from 2019 to 2021. Data on disease severity, clinical manifestations, mortality, and underlying disorders were collected and analyzed using the SPSS software version 22 at a 95% confidence interval and 0.05 sig-nificance level. Result(s) The study included 9653 men (48%) and 10332 women (52%). Patients with chronic kidney diseases, cancer, chronic obstruc-tive pulmonary disease, hypertension, cardiovascular disease, and diabetes were at higher mortality risk than those without these underlying diseases, respectively. However, there was no significant relationship between asthma and mortality. Also, age > 50 years, male gender, oxygen saturation < 93 on admission, and symptoms lasting <= 5 days were associated with increased mortality. Conclusion(s) Since patients with underlying diseases are at higher mortality risk, they should precisely follow the advice provided by health authorities and receive a complete COVID-19 vaccination series.Copyright © 2022, Author(s).
Keywords
Comorbidity, Coronavirus, Mortality, SARS-CoV-2, adult, aged, article, asthma, chronic kidney failure, chronic obstructive lung disease, cohort analysis, coronavirus disease 2019, diabetes mellitus, female, human, hypertension, major clinical study, male, malignant neoplasm, middle aged, mortality risk, oxygen saturation, retrospective study, very elderly, angiotensin receptor antagonist/cb [Drug Combination], angiotensin receptor antagonist/pv [Special Situation for Pharmacovigilance], antiangina pectoris agent/cb [Drug Combination], antiangina pectoris agent/pv [Special Situation for Pharmacovigilance], antiarrhythmic agent/pv [Special Situation for Pharmacovigilance], anticoagulant agent/cb [Drug Combination], anticoagulant agent/pv [Special Situation for Pharmacovigilance], beta 2 adrenergic receptor blocking agent/cb [Drug Combination], beta 2 adrenergic receptor blocking agent/pv [Special Situation for Pharmacovigilance], beta adrenergic receptor blocking agent/pv [Special Situation for Pharmacovigilance], calcium channel blocking agent/cb [Drug Combination], calcium channel blocking agent/pv [Special Situation for Pharmacovigilance], corticosteroid/cb [Drug Combination], corticosteroid/pv [Special Situation for Pharmacovigilance], dipeptidyl carboxypeptidase inhibitor/cb [Drug Combination], dipeptidyl carboxypeptidase inhibitor/pv [Special Situation for Pharmacovigilance], dipeptidyl peptidase IV inhibitor/cb [Drug Combination], dipeptidyl peptidase IV inhibitor/pv [Special Situation for Pharmacovigilance], diuretic agent/cb [Drug Combination], diuretic agent/pv [Special Situation for Pharmacovigilance], glibenclamide/cb [Drug Combination], glibenclamide/pv [Special Situation for Pharmacovigilance], gliclazide/cb [Drug Combination], gliclazide/pv [Special Situation for Pharmacovigilance], insulin/pv [Special Situation for Pharmacovigilance], leukotriene receptor stimulating agent/cb [Drug Combination], leukotriene receptor stimulating agent/pv [Special Situation for Pharmacovigilance], metformin/cb [Drug Combination], metformin/pv [Special Situation for Pharmacovigilance], muscarinic receptor blocking agent/pv [Special Situation for Pharmacovigilance], sodium glucose cotransporter 2 inhibitor/cb [Drug Combination], sodium glucose cotransporter 2 inhibitor/pv [Special Situation for Pharmacovigilance]

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Experimental Studies Language: English Journal: Jundishapur Journal of Microbiology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Experimental Studies Language: English Journal: Jundishapur Journal of Microbiology Year: 2022 Document Type: Article